Herantis Pharma Oyj - Asset Resilience Ratio

Latest as of June 2025: 89.18%

Herantis Pharma Oyj (HRTIS) has an Asset Resilience Ratio of 89.18% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Herantis Pharma Oyj total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€4.56 Million

≈ $5.33 Million USD Cash + Short-term Investments

Total Assets

€5.11 Million

≈ $5.98 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how Herantis Pharma Oyj's Asset Resilience Ratio has changed over time. See Herantis Pharma Oyj net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Herantis Pharma Oyj's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Herantis Pharma Oyj stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€446.00K	8.72%
Short-term Investments	€4.11 Million	80.46%
Total Liquid Assets	€4.56 Million	89.18%

Asset Resilience Insights

Very High Liquidity: Herantis Pharma Oyj maintains exceptional liquid asset reserves at 89.18% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Herantis Pharma Oyj Industry Peers by Asset Resilience Ratio

Compare Herantis Pharma Oyj's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Xizang Haisco Pharmaceutical Group Co Ltd SHE:002653	Biotechnology	2.21%
CSL Ltd AU:CSL	Biotechnology	0.41%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Crispr Therapeutics AG NASDAQ:CRSP	Biotechnology	74.05%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Ascendis Pharma AS F:A71	Biotechnology	0.00%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	13.57%

Annual Asset Resilience Ratio for Herantis Pharma Oyj (2012–2024)

The table below shows the annual Asset Resilience Ratio data for Herantis Pharma Oyj.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	83.02%	€2.13 Million ≈ $2.50 Million	€2.57 Million ≈ $3.01 Million	-13.16pp
2023-12-31	96.18%	€6.49 Million ≈ $7.59 Million	€6.75 Million ≈ $7.89 Million	+0.06pp
2022-12-31	96.13%	€5.99 Million ≈ $7.00 Million	€6.23 Million ≈ $7.29 Million	+14.98pp
2020-12-31	81.15%	€13.32 Million ≈ $15.58 Million	€16.42 Million ≈ $19.20 Million	+72.25pp
2019-12-31	8.90%	€985.24K ≈ $1.15 Million	€11.07 Million ≈ $12.94 Million	-11.62pp
2018-12-31	20.52%	€1.47 Million ≈ $1.71 Million	€7.15 Million ≈ $8.36 Million	-25.38pp
2017-12-31	45.90%	€5.31 Million ≈ $6.21 Million	€11.57 Million ≈ $13.53 Million	+25.84pp
2016-12-31	20.06%	€2.05 Million ≈ $2.39 Million	€10.21 Million ≈ $11.93 Million	-15.43pp
2015-12-31	35.49%	€5.00 Million ≈ $5.85 Million	€14.09 Million ≈ $16.47 Million	+4.98pp
2014-12-31	30.51%	€9.00 Million ≈ $10.52 Million	€29.49 Million ≈ $34.48 Million	--
2012-12-31	0.00%	€0.00 ≈ $0.00	€2.21 Million ≈ $2.59 Million	--

pp = percentage points

About Herantis Pharma Oyj

HE:HRTIS Finland Biotechnology

Market Cap

$54.84 Million

€46.91 Million EUR

Market Cap Rank

#21646 Global

#108 in Finland

Share Price

€1.77

Change (1 day)

+1.14%

52-Week Range

€1.23 - €2.78

All Time High

€10.10